Here are the Form 4 insider transactions from Sanofi (SNY) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SNY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SNY filings page.
Sanofi, through wholly owned subsidiaries, converted 782,855 shares of Attovia Therapeutics Series C preferred stock into 782,855 shares of common stock automatically upon Attovia’s IPO on August 6, 2026, and also purchased 300,000 common shares in the IPO at $17.00 per share. Following the IPO, Sanofi stated its beneficial ownership fell below 10% due to additional common shares issued.